相关实验视频
Updated: Jun 9, 2026

07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
长期使用内分泌素受体抗剂可改善早期动脉样硬化患者的冠状动脉内分泌功能
Martin Reriani1, Eugenia Raichlin, Abhiram Prasad
1Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First St SW, Rochester, MN 55905, USA.
Circulation
|August 25, 2010
概括
长期用阿特拉森坦 (endothelin-A受体对抗剂) 治疗,显著改善了早期动脉样硬化患者的冠状动脉血流. 这表明,在这种情况下,内皮细胞系统在调节内皮细胞功能方面发挥着关键作用.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 医学研究 医学研究
背景情况:
- 恩多林-1 (ET-1) 是一种强大的血管收缩剂,涉及动脉样硬化病因.
- 内皮功能障碍是早期冠状动脉样硬化的标志.
- 目前正在研究内甲素-A (ET(A)) 受体对抗剂的治疗潜力.
研究的目的:
- 为了测试长期使用ET(A) 受体抗剂的治疗是否能改善早期冠状动脉样硬化患者的冠状动脉内皮功能.
- 评估阿特拉森坦对内皮依赖和独立血管扩张的影响.
- 评估内源性内甲蛋白系统在人类内皮功能中的作用.
主要方法:
- 一项双盲,安慰剂控制的研究,涉及47名患有早期冠状动脉样硬化和内皮功能障碍的患者.
- 患者接受了阿特拉塞坦 (10毫克) 或安慰剂6个月.
- 冠状动脉血管扩张被评估使用乙胆输液,与N ((G) -单甲基-l-阿尔金因在一个子组,和内皮独立的血管扩张与腺和酸甘油.
主要成果:
- 与安慰剂相比,阿特拉森坦治疗导致冠状动脉血流响应乙胆显著改善 (39.67%vs-2.22%).
- 两组之间冠状动脉直径变化或冠状动脉流量储备没有显著差异.
- 在阿特拉森坦和安慰剂组中,不良反应和基线特征在阿特拉森坦和安慰剂组之间相似.
结论:
- 六个月的阿特拉森坦治疗有效地改善了早期动脉样硬化患者的冠状动脉微血管内皮功能.
- 这些发现支持了内源性内甲蛋白系统在调节人类动脉样硬化中的内皮功能方面的关键作用.
- 该研究提供了ET(A) 受体对抗作用在治疗早期冠状动脉疾病中的治疗潜力的证据.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...